While MS itself does not increase the risk of contracting COVID-19, treatment decisions should be individualized and made collaboratively between the patient and his or her healthcare provider during the current pandemic. It is imperative that clinicians recognize which patients will benefit from which disease-modifying therapies (DMTs), and that they address patient concerns and provide tools on what patients can do at home with family and caregivers.
This CMEOCast podcast focuses on treating patients with MS in accordance with current guidelines, including evaluating and assessing COVID-19 disease severity and individualizing therapeutic strategy based on patient, disease, and drug factors. Access this activity for credit here:
